Thus, the combination of OX40L/PPT with PD-1 immune checkpoint blockade resulted in significant treatment efficiency enhancement in CT26 subcutaneous colon cancer model, and led to protective immunity against CT26gfp colon cancer cells. Here, PDCD1 is linked to malignant colon neoplasm.